|
|
Blood, 15 May 2006, Vol. 107, No. 10, pp. 4171-4176.
Prepublished online as a Blood First Edition Paper on February 7, 2006January 31, 2006; DOI 10.1182/blood-2005-08-3320.
 Previous Article | Next Article 
Submitted August 16, 2005
Accepted November 28, 2005
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukemia: An attempt to define patients who may not require further therapy
Jaspal Kaeda, Richard M Szydlo, Derville O'Shea, Eduardo Olavarria, Francesco Dazzi, David Marin, Susan Saunders, Jamshid S Khorashad, Nicholas C Cross, John M Goldman*, and Jane F Apperley
Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
National Genetics Reference Laboratory, University of Southampton, Salisbury, United Kingdom
* Corresponding author; email: goldmanj2{at}nhlbi.nih.gov.
We identified 243 patients with Ph-positive CML who had BCR-ABL transcripts monitored by quantitative RT-PCR after allogeneic stem cell transplant for a median of 84.3 months. Individual patients were regarded as having achieved molecular relapse (MR) if the BCR-ABL/ABL ratio exceeded 0.02% on three occasions or reached 0.05% on two occasions. Patients were allocated to one of four categories: (1) 36 patients were 'persistently negative' or had a single low level positive result, (2) 51 patients, 'fluctuating positive, low level', had more than one positive result but never more than two consecutive positive results; (3) 27 patients, 'persistently positive, low level', had persisting low levels of BCR-ABL transcripts but never more than three consecutive positive results, and (4) 129 patients relapsed. In 107 of these relapse was based initially only on molecular criteria; in 72 (67.3%) patients the leukemia progressed to cytogenetic or hematologic relapse either prior to or during treatment with donor lymphocyte infusions. We conclude that the pattern of BCR-ABL transcript levels after allograft is variable; only a minority of patients with fluctuating or persistent low levels of BCR-ABL transcript satisfied our definitions of MR whereas the majority of patients who did so were likely to progress further.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Durable responses to imatinib in patients with PDGFRB fusion gene–positive and BCR-ABL–negative chronic myeloproliferative disorders
- Marianna David, Nicholas C. P. Cross, Sonja Burgstaller, Andrew Chase, Claire Curtis, Raymond Dang, Martine Gardembas, John M. Goldman, Francis Grand, George Hughes, Francoise Huguet, Louise Lavender, Grant A. McArthur, Francois X. Mahon, Giorgio Massimini, Junia Melo, Philippe Rousselot, Robin J. Russell-Jones, John F. Seymour, Graeme Smith, Alastair Stark, Katherine Waghorn, Zariana Nikolova, and Jane F. Apperley
Blood 2007 109: 61-64.
[Abstract]
[Full Text]
[PDF]
-
Transplantation for CML: lifelong PCR monitoring?
- Richard T. Maziarz
Blood 2006 107: 3820.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. C. Bene and J. S. Kaeda
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet
Haematologica,
August 1, 2009;
94(8):
1135 - 1150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hayat, S. R. McCann, S. Langabeer, S. Irvine, M. F. McMullin, and E. Conneally
Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation
Haematologica,
February 1, 2009;
94(2):
296 - 298.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Marin, D. Milojkovic, E. Olavarria, J. S. Khorashad, H. de Lavallade, A. G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, et al.
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
Blood,
December 1, 2008;
112(12):
4437 - 4444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Khorashad, H. de Lavallade, J. F. Apperley, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al.
Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression
J. Clin. Oncol.,
October 10, 2008;
26(29):
4806 - 4813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. de Lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al.
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis
J. Clin. Oncol.,
July 10, 2008;
26(20):
3358 - 3363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Olavarria, S. Siddique, M. J. Griffiths, S. Avery, J. L. Byrne, K. P. Piper, A. L. Lennard, L. Pallan, J. M. Arrazi, J. B. Perz, et al.
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Blood,
December 15, 2007;
110(13):
4614 - 4617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Palandri, I. Iacobucci, F. Quarantelli, F. Castagnetti, D. Cilloni, M. Baccarani, and on behalf of the GIMEMA Working Party on CML
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
Haematologica,
November 1, 2007;
92(11):
1579 - 1580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Clin. Cancer Res.,
October 15, 2007;
13(20):
6136 - 6143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. M. Yong, K. Rezvani, B. N. Savani, R. Eniafe, S. Mielke, J. M. Goldman, and A. J. Barrett
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
Blood,
July 15, 2007;
110(2):
770 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kroger, A. Badbaran, E. Holler, J. Hahn, G. Kobbe, M. Bornhauser, A. Reiter, T. Zabelina, A. R. Zander, and B. Fehse
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
Blood,
February 1, 2007;
109(3):
1316 - 1321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology,
January 1, 2007;
2007(1):
376 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. David, N. C. P. Cross, S. Burgstaller, A. Chase, C. Curtis, R. Dang, M. Gardembas, J. M. Goldman, F. Grand, G. Hughes, et al.
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders
Blood,
January 1, 2007;
109(1):
61 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al.
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Blood,
July 1, 2006;
108(1):
28 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Apperley
Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation
Hematology,
January 1, 2006;
2006(1):
226 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
